Pfizer's weight-loss pill could be as effective as Novo Nordisk's Ozempic
A phase II trial shows that Pfizer’s candidate induces a similar weight loss to that of type 2 diabetes treatment Ozempic.
by marketwire, translated by daniel pedersen
An oral drug candidate, danuglipron, from Pfizer has demonstrated a similar weight-loss effect to Danish drugmaker Novo Nordisk’s best-selling type 2 diabetes treatment, Ozempic (semaglutide), which is injected once weekly.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to submit obesity tablet for approval this year
For subscribers
Jefferies: Semaglutide data is "reassuring"
For subscribers
